Christopher J. DeRespino
Christopher J. DeRespino is Adverum’s chief business officer, responsible for corporate strategy and global business development initiatives. Mr. DeRespino has more than 15 years of experience in the biopharmaceutical industry with significant expertise in screening, assessment, due diligence, negotiation, and deal execution. Most recently, he served as executive director of business development Amgen, responsible for evaluating and negotiating product transactions, partnerships, and potential acquisitions, co-leading the business development transactions function as a member of Amgen’s business development leadership team. Prior to Amgen, Mr. DeRespino was director asset acquisition/business development at Onyx Pharmaceuticals, joining Amgen as part of the company’s $10.4B acquisition of Onyx. Mr. DeRespino joined Onyx from Pfizer, where he was director of business development evaluation and strategy and supported numerous transactions across a wide spectrum of therapeutic areas and geographies. Mr. DeRespino began his career in management consulting at CSC Global Health Solutions where he collaborated with pharmaceutical organizations and leading academic medical centers on strategic plans, investment decisions, potential partnerships, and operational initiatives. Mr. DeRespino earned his M.B.A. from New York University’s Leonard N. Stern School of Business and a B.S.E. in biomedical engineering from The Johns Hopkins University.